Clinical trials: Patients With Cancer
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
This is a phase I/II clinical trial to determine the maximum tolerated dose (MTD) of total marrow irradiation (TMI) followed by fludarabine in the context of a myeloablative conditioning regimen for allogeneic hematopoietic stem…
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT05201183
- Testing
- Fludarabine + Total Marrow Irradiation
- Where
- United States
- Sponsor
- Naoyuki G. Saito, M.D., Ph.D.
Head and Neck Cancer
A Study in Head and Neck Cancer
This study will begin with a 30 participant lead-in part: these 30 participants will receive cetuximab manufactured by ImClone on a weekly basis in combination with other chemotherapy drugs [cisplatin or carboplatin plus…
- Trial name
- NCT01081041
- Testing
- Cetuximab, Cisplatin, Carboplatin
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Tumor, Carcinogens
Collection of Tissue Blocks or Slides From Patients With Cancer
BACKGROUND: Cancer of any type is a serious disease and despite all the progress made from past research, there is still much that is poorly understood at the molecular level.
- Conditions
- Tumor, Carcinogens, Neoplasm, Benign, Benign Neoplasms
- Trial name
- NCT02810405
- Where
- United States
- Volunteers
- 191 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Glioma
Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 24 months.
- Trial name
- NCT01792505
- Testing
- Dendritic Cell Vaccine in combination with Imiquimod cream
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Cedars-Sinai Medical Center
Acute Myeloid Leukemia, Non-hodgkin's Lymphoma
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
- Conditions
- Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT04662294
- Testing
- CD70 CAR T-cells
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhejiang University
Myelodysplastic Syndromes
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
The primary endpoint of this study is to estimate morphologic complete remission rate. Estimation of response rate is also a secondary objection.
- Trial name
- NCT00384956
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Sarcoma, Soft Tissue
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
The primary purpose of the study is to estimate the time from the first dose of LY573636-sodium (hereafter referred to as LY573636) to the date your physician determines that your disease has progressed or worsened.
- Trial name
- NCT00490451
- Testing
- LY573636-sodium
- Where
- 13 sites in United States, Argentina and 1 more
- Volunteers
- 101 people
- Sponsor
- Eli Lilly and Company
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054288
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Melanoma (Skin)
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00003027
- Testing
- aldesleukin, filgrastim, recombinant interferon alfa
- Where
- 94 sites in United States
- Volunteers
- 482 people
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
This is an open-label, non-randomized Phase 1 study evaluating the role of two regimens: A) Nivolumab in combination with Pomalidomide and low dose dexamethasone and B) Nivolumab + Elotuzumab + Pomalidomide + dexamethasone in the…
- Trial name
- NCT03023527
- Testing
- Nivolumab, Pomalidomide, Dexamethasone
- Where
- 12 sites in Spain
- Volunteers
- 6 people
- Sponsor
- PETHEMA Foundation
Pancreatic Neoplasms, Pancreatic Cancer
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Background: Stereotactic body radiation therapy (SBRT) is used to treat cancer. It is a way of giving very focused beams of radiation to tumors.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas
- Trial name
- NCT02311361
- Testing
- Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.
- Trial name
- TUNINTIL-2 (NCT06961786)
- Testing
- TILT-123, TIL, Cyclophosphamide
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- TILT Biotherapeutics Ltd.
Advanced Solid Tumors, Excluding Breast Cancer
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
This is a multi-center, open-label, single-sequence, crossover, drug-drug interaction (DDI) study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on the PK of dovitinib in patients with advanced solid tumors, excluding…
- Trial name
- CTKI258A2120 (NCT01700270)
- Testing
- dovitinib (TKI258), fluvoxamine
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Pegasys in Patients With Chronic Myeloid Leukemia (CML)
The goal of this clinical research study is to learn if adding pegylated interferon-alfa 2a (Pegasys) to the TKI that you are already receiving can help to control CML.
- Trial name
- NCT01392170
- Testing
- PEG-IFNá-2a
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.
- Trial name
- NCT01259869
- Testing
- PX-866
- Where
- 7 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Esophageal Cancer
Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal Cancer
Participants in this study will have esophageal cancer that has spread (metastasized) to other parts of the body either at initial diagnosis (synchronous) or after the cancer returned following treatment (recurrent).
- Trial name
- NCT07330583
- Testing
- Stereotactic body radiation treatment (SBRT)
- Volunteers
- 22 people
- Sponsor
- AHS Cancer Control Alberta
Leukemia
Symptom Burden in Chronic Myeloid Leukemia (CML)
Objectives: The objective of this study is to measure and delineate the symptom burden experienced by patients with chronic myeloid leukemia (CML). The Primary Aim is to develop and validate an M. D.
- Trial name
- NCT01046305
- Testing
- Interview & Questionnaires, Rating Questionnaire, MDASI-CML Questionnaire
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Testicular Cancer
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
Germ cell tumors, a relatively rare disease, but most common malignancy in young males, occur most frequently in testis. The incidence is about 1%, but is increasing in the majority of developed countries.
- Trial name
- GCT (NCT00772694)
- Testing
- sorafenib
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Fondation Wygrajmy Zdrowie
Lambert Eaton Myasthenic Syndrome
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
- Trial name
- NCT01377922
- Testing
- Amifampridine Phosphate
- Where
- 14 sites in United States, France and 6 more
- Volunteers
- 38 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Ovarian Cancer, Peritoneal Cancer
Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane
A randomized study of chemotherapy versus hormonal treatment in patients with ovarian cancer resistant or refractory to platinum and taxane.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Cancer of the Fallopian Tube
- Trial name
- NCT02728622
- Testing
- Tamoxifen, Chemotherapy
- Volunteers
- 241 people
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.